Research Topics
| M DucreuxSummaryAffiliation: Institut Gustave Roussy Country: France Publications
| Collaborators
|
Detail Information
Publications
Emerging drugs in pancreatic cancerMichel Ducreux
Unité de Gastroentérologie, Institut Gustave Roussy, Villejuif, France
Expert Opin Emerg Drugs 9:73-89. 2004....
Combination chemotherapy in advanced small bowel adenocarcinomaChristophe Locher
Gastroenterology Unit, Institut Gustave Roussy, Villejuif, France
Oncology 69:290-4. 2005..CONCLUSION: Chemotherapy with 5-FU and platinum compounds seems effective and well-tolerated in patients with advanced SBA. 5-FU-irinotecan combination chemotherapy deserves further investigation in the first-line setting...
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II studySamy Louafi
Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Cancer 109:1384-90. 2007..In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated...
Treatment of advanced pancreatic cancerMichel Ducreux
Gastroenterology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
Semin Oncol 34:S25-30. 2007..Further advances will probably be made with combinations of targeted therapies. Better understanding of the carcinogenesis of this very aggressive cancer is also needed...
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survivalLucie Oberic
Institut Gustave Roussy, Villejuif, France
Radiat Oncol 6:124. 2011..We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued...
[Treatment strategy of neuroendocrine tumors]Michel Ducreux
Unité de gastroentérologie Institut Gustave Roussy 94805 Villejuif
Rev Prat 52:290-6. 2002..Gastrinoma and other pancreatic tumours arising in the context of multiple endocrine neoplasia type I disease need a specific therapeutic strategy...
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancerMichel Ducreux
Department of Medicine, Gustave Roussy Institute, Villejuif, France
Int J Cancer 128:682-90. 2011..47%), febrile neutropenia (0% vs. 6%) and neuropathy (11% vs. 26%) than FOLFOX-6 patients. We conclude that XELOX is non-inferior in terms of efficacy to FOLFOX-6 in the first-line treatment of MCRC, but has a different toxicity profile...
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trialMichel Ducreux
Institut Gustave Roussy, Paris, France
Lancet Oncol 12:1032-44. 2011..Our aim was to investigate whether combination treatment is better than the sequential administration of the same drugs in patients with advanced colorectal cancer...
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux
Institut Gustave Roussy, Service d Oncologie Digestive, Villejuif, France
Ann Oncol 13:1185-91. 2002..5% response rate and a 29% survival rate at 1 year. The present study aimed to compare FUP with 5-FU alone, which was the control arm in former Mayo Clinic trials...
[Docetaxel and gastric cancer]Michel Ducreux
Unité de Gastroentérologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif
Bull Cancer 91:257-61. 2004..With a high activity in terms of radiosensitization, docetaxel could also become a major drug in the design of new radiochemotherapy protocols for neoadjuvant or adjuvant disease...
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?Michel Ducreux
Institut Gustave Roussy, Villejuif, France
Oncology 74:17-24. 2008..Conclusion: HD-irinotecan plus LV5FU2 or HD-FOLFIRI is feasible and achieved a high response rate and postsurgery complete response rate...
[Non-invasive imaging tools in colorectal cancer]Michel Ducreux
Service de cancérologie digestive, Institut Gustave Roussy, 94805 Villejuif Cedex, France
Rev Prat 60:1071-3. 2010..Its role in early determination of therapeutic response should be evaluated...
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]Michel Ducreux
Unité de cancérologie digestive, Institut Gustave Roussy, Département de cancérologie, Hopital Paul Brousse, Villejuif, université de médecine Paris XI, Kremlin Bicetre
Bull Cancer 95:931-4. 2008..It must be emphasised that, for the first time in 2008, it is possible to prescribe targeted therapies to a specific "targeted" group of patients with metastatic colorectal cancer...
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]Michel Ducreux
Departement de Medecine, Institut Gustave Roussy, 94805 Villejuif
Rev Prat 60:219-23. 2010..Some cancers did not follow this rule because, for instance, the screening and early diagnosis of lung cancer among smokers is still a failure even when using the scanner...
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trialM Ducreux
Unité de Gastroentérologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
Eur J Cancer 41:398-403. 2005..These results are not sufficient to start a phase III trial. However, our group is planning a phase III trial comparing 5FU+folinic acid versus the same schedule+oxaliplatin a platinum analogue...
Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trialM Ducreux
Institut Gustave Roussy, Villejuif, France
Oncology 70:222-30. 2006....
The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cureMichel Ducreux
Unité de Gastroentérologie, Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Best Pract Res Clin Gastroenterol 21:997-1014. 2007..For advanced disease, chemotherapy alone has given very disappointing results. A multidisciplinary approach combining biological assessment of targets with clinical trials to evaluate new targeted drugs should be considered...
[Colon and rectal tumours]Michel Ducreux
Service d'Oncologie Digestive, Institut Gustave Roussy, 94805 Villejuif
Rev Prat 55:1241-7. 2005
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le CancerMichel Ducreux
Gastrointestinal Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
J Clin Oncol 23:4881-7. 2005....
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patientsD Elias
Department of Surgical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Ann Oncol 15:781-5. 2004..We report preliminary results on survival in a phase II study using oxaliplatin (LOHP)...
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapyD Elias
Department of Oncological Surgery, Gustave Roussy Institute, Villejuif, France
Cancer 92:71-6. 2001..A new approach that combines maximal surgery with maximal regional chemotherapy has potential to cure selected patients who have colorectal PC. The authors have reported the oncologic results of this combined treatment...
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancerD Fallik
Institut Gustave Roussy, Villejuif, France
Ann Oncol 14:856-63. 2003..This treatment seems to prevent extra-hepatic spread and prolong survival time. The results of this study have to be confirmed by new trials using more active systemic chemotherapy...
Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and toleranceD Elias
Department of Surgical Oncology, Institut Gustave Roussy Comprehensive Cancer Center, Villejuif, France
Ann Oncol 15:1558-65. 2004..CONCLUSION: Intraperitoneal heated oxaliplatin (460 mg/m(2)) plus irinotecan (400 mg/m(2)) presented an advantageous PK profile and was tolerated by patients, despite a high hematological toxicity rate...
Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liverD Elias
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
Eur J Surg Oncol 35:1092-7. 2009..It is an extensive application of the current guidelines...
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiersM Ducreux
Institut Gustave Roussy, Villejuif, France
Ann Oncol 14:ii17-23. 2003..In vitro, the cyclin-dependent kinase inhibitor flavopiridol enhances the induction of apoptosis by chemotherapy. Clinically, it can safely be administered with irinotecan, and studies in CRC are planned...
The differential response to chemotherapy of ovarian metastases from colorectal carcinomaD Goere
Department of Surgical Oncology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, Cedex, France
Eur J Surg Oncol 34:1335-9. 2008....
Prognostic factors for chemoembolization in liver metastasis from endocrine tumorsA Roche
Department of Interventional Radiology, Institut Gustave Roussy, Villejuif Cedex, France
Hepatogastroenterology 51:1751-6. 2004..The aims of this study were to assess response rates, evaluate side effects and determine prognostic factors for both response and toxicity in patients with liver metastasis from endocrine tumors treated with chemoembolization...
[Resectional treatment of peritoneal carcinomatosis followed by intraperitoneal chemotherapy, practical aspects]D Elias
Département de chirurgie digestive carcinologique, Institut Gustave Roussy, Villejuif
J Chir (Paris) 140:270-6. 2003..If these conditions can be met, peritoneal metastases can be definitively cured in two thirds of colorectal PC and pseudomyxoma peritonei, and in nearly half of mesotheliomas...
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trialV Boige
Gastrointestinal Oncology Unit, Institut Gustave Roussy, Villejuif, France
Br J Cancer 97:862-7. 2007..However, the manageable toxicity profile and the encouraging disease control rate deserve further attention for this convenient, outpatient-based chemotherapy regimen...
Radiotherapy for localized rectal cancerE Deutsch
Department of Radiation Therapy Institut Gustave Roussy, Villejuif, France
Ann Oncol 18:ix105-13. 2007
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatinE Mitry
Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France
Br J Cancer 81:1351-5. 1999..However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed...
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumoursT Aparicio
, Institut Gustave Roussy, 94805, Villejuif, France
Eur J Cancer 37:1014-9. 2001..A slow tumour growth rate before treatment is predictive of a good response to somatostatin analogues which could be considered an option for first-line treatment...
Central retroperitoneal recurrences from colorectal cancer: are lymph node and locoregional recurrences the same disease?F Dumont
Department of Digestive Oncological Surgery, Institut Gustave Roussy, Villejuif, France
Eur J Surg Oncol 38:611-6. 2012..A CRR is sometimes defined as a locoregional recurrence (LR) and sometimes as a lymph node recurrence (NR). This study was conducted to determine the nature of CRR and evaluate prognostic factors after complete CRR resection...
Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal originD Elias
Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France
Br J Surg 91:455-6. 2004
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patientsM Ducreux
Institut Gustave Roussy, Villejuif, France
Ann Oncol 15:467-73. 2004..CONCLUSIONS: With a 10% response rate, median overall survival of 9 months and an encouraging safety profile, the OXFU combination is effective, appears superior to infusional 5-FU and warrants further studies in APC patients...
[Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]C Locher
, Institut Gustave-Roussy, Villejuif, France
Gastroenterol Clin Biol 25:749-54. 2001..In this study, toxicity was probably overestimated due to the small number of patients. More patients are necessary in order to better estimate the cost of toxicity of these chemotherapies...
Impact of chromogranin A measurement in the work-up of neuroendocrine tumorsE Baudin
Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:S79-82. 2001..Both tumor burden and secretory activity should be taken into account when interpreting CgA results...
Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumorsE Baudin
Nuclear Medicine, Institut Gustave Roussy, Villejuif, France
J Clin Endocrinol Metab 84:69-75. 1999..Routine hormonal measurements should depend on the primary site. NSE, 5-HIAA, CT, and alphaGP should be routinely measured in foregut-derived NET; only serum NSE and 5-HIAA measurements are recommended in midgut-derived NET...
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinomaJ Taieb
Departement de Medecine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 13:1192-6. 2002..Unresectable biliary tract carcinoma (BTC) is associated with a very poor prognosis. To improve efficacy and tolerance of the 5-fluorouracil (5-FU)/cisplatin combination in BTC, we designed a new therapeutic schedule, the LV5FU2-P regimen...
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumoursT Aparicio
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Eur J Surg Oncol 30:1098-103. 2004..A peri-tumoral resection confers a high risk of local recurrence and should be avoided. Lymphadenectomy is not systematic. Grade is the main prognostic factor for OS and can be a decision marker for adjuvant treatment with Gleevec...
Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-cathetersF Deschamps
Department of Interventional Radiology, Gustave Roussy Institut, Villejuif, France
Cardiovasc Intervent Radiol 34:973-9. 2011..To compare retrospectively the safety and efficacy of percutaneous and surgical implantations of port-catheters for intra-arterial hepatic chemotherapy (IAHC)...
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastasesRobbert J de Haas
Centre Hepato Biliaire, AP HP Hopital Paul Brousse, Villejuif, France
Ann Surg Oncol 17:1010-23. 2010....
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failureValerie Boige
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Surg Oncol 15:219-26. 2008..Whether this regimen could be beneficial after systemic chemotherapy failure is unknown...
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?Th Delaunoit
Department of Gastroenterology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Eur J Cancer 40:515-20. 2004..7 months, and suggests that it could be considered as a valid option in first-line therapy...
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumabD Malka
Gastrointestinal Oncology Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Ann Oncol 23:919-27. 2012..We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients...
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]V Boige
, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif Cedex, France
Gastroenterol Clin Biol 32:3-7. 2008
Adjuvant chemotherapy for colon cancerM Ducreux
Gastroenterology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
Best Pract Res Clin Gastroenterol 16:283-98. 2002..Current clinical trials are evaluating the role of non-fluorinated pyrimidine agents in an adjuvant setting...
Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastasesD Elias
Department of Oncologic Surgery, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
J Surg Oncol 69:88-93. 1998..The true impact of the width of the margin on the prognosis is unclear...
Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graftM Pocard
Department of Surgical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Eur J Surg Oncol 33:459-62. 2007..The aim of this study was to compare functional results and quality of life (QoL) of two salvage techniques: coloanal anastomosis (CAA) or perineal reconstruction after abdominoperineal resection for very low rectal cancer...
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosisD Elias
Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France
Oncology 63:346-52. 2002..p.) oxaliplatin (LOHP) solution and its safety profile in increasingly hypotonic solutions. This is the first clinical study of i.p. chemohyperthermia with hypotonic solutions...
Treatment of advanced gastric cancer: where we are in 2003Michel Ducreux
Onkologie 26:214-5. 2003
Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancerD Elias
Department of Oncologic Digestive Surgery and Digestive Oncology, Institut Gustave Roussy, Cancer Center Hospital, rue Camille Desmoulins, 94805 Villejuif Cedex, France
Eur J Surg Oncol 32:632-6. 2006..To report our experience of peritoneal carcinomatosis (PC) discovered during abdominal exploration in patients with liver metastases (LM)...
Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationaleG Liberale
Department of Surgical Oncology, Gustave Roussy Institute IGR, Centre de lutte contre le cancer, Villejuif, France
Acta Chir Belg 106:291-6. 2006..Those patients should no longer be considered as patients with a terminal disease but as patients with a potentially treatable localized disease...
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancerK Fizazi
Institut Gustave Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France
J Clin Oncol 18:2293-300. 2000....
Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosisD Elias
Department of Surgical Oncology, Institut Gustave Roussy, Cedex, France
Ann Surg 254:289-93. 2011....
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective studyM Saghatchian
Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:535-40. 2001..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trialIsabelle Borget
Gustave Roussy Institute, Villejuif, France
Oncology 71:40-8. 2006..LD-LV5FU2 appeared a good alternative regimen because it reduced costs without jeopardizing its efficacy. The WI-FU regimen did not show a significant difference in terms of efficacy, but suggested toxicity to be slightly increased...
Results of lymphadenectomy for obvious lateroaortic lymph node metastases from colorectal primariesD Elias
Department of Digestive Oncological Surgery, Medical Oncology, and Radiotherapy, Institut Gustave Roussy, Comprehensive Cancer Center, Villejuif, France
Hepatogastroenterology 48:123-7. 2001..To analyze the results of surgery for macroscopically or radiologically obvious (i.e., easily detectable by computed tomography scan or by palpation) synchronous or metachronous lateroaortic lymph node metastases from colorectal primaries...
Gastric linitis adenocarcinoma and carcinomatous meningitis: an infrequent but aggressive association--report of four casesT Delaunoit
Service d Oncologie digestive Médicale, Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:869-71. 2001..Furthermore, the diagnosis of CM must be done as soon as possible because of the clear effectiveness of a therapeutic approach on the improvement of symptoms and quality of life...
[Positron emission tomography and gastrointestinal oncology]Michel Ducreux
Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex
Gastroenterol Clin Biol 27:B71-8. 2003
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]Thierry Conroy
Centre Alexis Vautrin, Nancy
Bull Cancer 91:759-68. 2004..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedulesJulien Taieb
Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Cancer 98:2664-70. 2003..Therefore, the authors evaluated the activity and toxicity of two such combinations in patients with HCC...
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]Jean Louis Legoux
Services d Hépato gastroentérologie, Hopital Haut Leveque, CHU de Bordeaux, Pessac
Gastroenterol Clin Biol 30:1191-5. 2006
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabAstrid Lievre
L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
J Clin Oncol 26:374-9. 2008..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distributionD Elias
Department of Surgical Oncology, Institut Gustave Roussy Comprehensive Cancer Center, Villejuif, France
Ann Oncol 13:267-72. 2002..Oxaliplatin has demonstrated significant activity in advanced colorectal cancer, and this is the first publication concerning its intraperitoneal administration...
Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphyS Leboulleux
Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Endocrinol Metab 93:3021-8. 2008....
A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatmentD Goere
Department of Surgical Oncology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex, France
Gastroenterol Clin Biol 32:649-52. 2008....
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumoursE Baudin
, Institut Gustave Roussy, Villejuif, France
Br J Cancer 78:1102-7. 1998..01). Among six patients with NET followed for 11-37 months, CgA appeared to be a better marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients...
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective studyDominique Elias
Department of Surgical Oncology, Comprehensive Cancer Center, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
Surgery 133:375-82. 2003..The number, size, and localization of the tumor sites are less important than performing a complete (or near-complete) resection...
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]Julien Taieb
Departement de Medecine, Institut Gustave Roussy, Villejuif, France
Gastroenterol Clin Biol 26:605-9. 2002..To prospectively evaluate efficacy and tolerance of the 5-fluorouracil + folinic acid + cisplatin (LV5FU2-P) combination in the treatment of unresectable pancreatic carcinoma...
[Linitis of the colon with peritoneal carcinosis treated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy]Hatem Salloum
Gastroenterol Clin Biol 31:68-9. 2007
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapyRene Adam
Centre Hépato Biliaire and the Department of Medical Oncology, Assistance Publique Hopitaux de Paris, France
J Clin Oncol 25:4593-602. 2007..This study was performed to determine the post-cetuximab resectability rate and to examine postoperative outcomes for these heavily pretreated patients...
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203Jean Pierre Gerard
Centre Antoine Lacassagne, Radiotherapy Department, Nice, France
J Clin Oncol 24:4620-5. 2006..In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy...
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 casesGabriel Liberale
Departement de Chirurgie Oncologique, CHU Charles Nicolle, Rouen
Gastroenterol Clin Biol 31:281-5. 2007..The SLN technique may be used to guide surgical resection (lymph mapping), restrict the lymph node analysis solely to the SLN (accuracy) and upgrade tumor staging when micrometastases are specifically detected in the SLN...
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trialFrancoise Mornex
département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon France
Int J Radiat Oncol Biol Phys 65:1471-8. 2006..Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation...
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I studyEric Francois
Department of Medical Oncology, Centre Antoine Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
Eur J Cancer 41:2861-7. 2005..The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies...
Immunogenic death of colon cancer cells treated with oxaliplatinA Tesniere
INSERM, U848, Villejuif, France
Oncogene 29:482-91. 2010..In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients...
Endocrine pancreatic tumours: which are the most useful MRI sequences?C Caramella
Department of Radiology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex, France
Eur Radiol 20:2618-27. 2010..To determine magnetic resonance imaging (MRI) signal and enhancement characteristics of endocrine pancreatic tumours (ETPs) and which MR sequences show them most consistently...
[Colorectal cancer: contribution of new diagnostic tools]Clarisse Dromain
, Institut Gustave Roussy, 94805 Villejuif
Rev Prat 54:151-4. 2004..It however will be necessary, in the years to come, to precisely evaluate the interest of this new method of imagery in the diagnosis of colorectal tumors, or in the follow-up of certain patients...
Malignant gastroduodenal obstruction: palliation with self-expanding metallic stentsBertrand Bessoud
Department of Medical and Interventional Imaging, Institut Gustave Roussy, Villejuif, France
J Vasc Interv Radiol 16:247-53. 2005..To evaluate the feasibility, efficacy, and tolerance of self-expanding metallic stent insertion under fluoroscopic guidance for palliation of symptoms related to malignant gastroduodenal obstruction...
Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomasBernard Paule
Hepato Biliary Center, Assistance Publique Hopitaux de Paris, Hopital Paul Brousse, Faculté de Médecine Paris Sud 11, Villejuif, France
Oncology 72:105-10. 2007..To assess the efficacy and safety of cetuximab in the palliative treatment of patients with intrahepatic cholangiocarcinomas (CCA) unresponsive to first-line gemcitabine-oxaliplatin (GEMOX) pretreatment...
The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional studyFranck Zenasni
Department of Psycho oncology, Institut Gustave Roussy, Villejuif, Paris, France
Support Care Cancer 17:1255-61. 2009..Hyperthermic intraperitoneal chemotherapy (HIPEC) after complete surgical resection is currently accepted as a therapeutic option for peritoneal carcinomatosis. However, considerable morbidity is reported after HIPEC...
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancerDavid Fallik
Department of Medicine, Institut Gustave Roussy, , Villejuif, France
Cancer Res 63:5738-44. 2003..001), indicating that MSI-driven inactivation of target genes modifies tumor chemosensitivity. Our observations allowed us to define the first useful predictive criteria for irinotecan response in patients with colorectal cancer...
An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancerCatherine Miquel
Department of Pathology, Saint-Anne Hospital, Paris, France
Hum Pathol 35:1564-7. 2004..Interestingly, the adenocarcinoma exhibited an MSI phenotype but the carcinoid tumor did not, indicating that these 2 tumors arose through different molecular pathways...
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)Jacqueline Duffour
CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier, France
Anticancer Res 26:3877-83. 2006..FP (5-FU combined with Cisplatin) as a first line chemotherapy in advanced oesophageal, gastric and pancreatic cancer...
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trialEmmanuel Mitry
CHU Ambroise Pare, Boulogne
Gastroenterol Clin Biol 30:357-63. 2006..The efficacy and benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma has never been demonstrated although it is regularly used...
Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601F Ferrand
Institut Gustave Roussy, Gastro Intestinal Unit, Department of Oncologic Medicine, Universite Paris Sud, Villejuif, France
Eur J Cancer 49:90-7. 2013..To assess the impact of primary tumour resection on overall survival (OS) of patients diagnosed with stage IV colorectal cancer (CRC)...
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunctionEric Raymond
Department of Medicine, Gustave Roussy Institute, Villejuif, France
J Clin Oncol 20:4303-12. 2002..To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia...
Regional chemotherapeutic techniques for liver tumors: current knowledge and future directionsDominique Elias
Division of Surgical Oncology, Department of Surgery, Gustave Roussy Institute, rue Camille Desmoulins, 94805, Villejuif, France
Surg Clin North Am 84:607-25. 2004..At the same time, resectability rates are increasing with the assistance of local ablative physical treatments such as radiofrequency, resulting in an improvement of patients' median survival rates and quality of life...
Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomyDominique Elias
Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France
J Surg Oncol 86:4-9. 2004..Our study was aimed at assessing the evolution of these metastases when they were also not found during liver surgery...
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumorsAlain Roche
Service de Radiologie Interventionnelle, Institut Gustave Roussy, rue Camille Desmoulins 39, 94805 Villejuif Cedex, France
Eur Radiol 13:136-40. 2003..Long-term palliation is possible in unresectable liver metastases from digestive neuroendocrine tumors with a few sessions of TACE as first-line and eventually exclusive treatment...
Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma stagingRonan Abgral
Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
J Clin Endocrinol Metab 96:665-71. 2011....
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinomaCosimo Durante
Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
Endocr Relat Cancer 16:585-97. 2009..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
[Colorectal cancer: prognostic molecular markers]Valerie Boige
Unité de Gastro Entérologie, Institut Gustave Roussy, Villejuif
Gastroenterol Clin Biol 28:21-32. 2004
Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionalityFrederic Deschamps
Interventional Radiology Department, Gustave Roussy Institut, Villejuif, France
J Vasc Interv Radiol 21:1681-8. 2010..To evaluate the feasibility, functionality, and dysfunctions of an arterial port catheter implanted via the femoral artery...
Results of R0 resection for colorectal liver metastases associated with extrahepatic diseaseDominique Elias
Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France
Ann Surg Oncol 11:274-80. 2004..This study reports the long-term outcome and prognostic factors of patients undergoing extrahepatic disease resection simultaneously with hepatectomy for liver metastases...
Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastasesDiane Goere
Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
Ann Surg 251:686-91. 2010..The aim of this study was to analyze the impact of hepatic arterial infusion (HAI) of oxaliplatin with systemic 5-Fluorouracil and leucovorin on patients with isolated unresectable liver metastases...
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary resultsNathalie Lassau
Department of Imaging, Ultrasonography Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Radiology 258:291-300. 2011....
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Valerie Boige
Department of Medicine, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 28:2556-64. 2010....
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-upClarisse Dromain
Department of Radiology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Radiology 223:255-62. 2002....
[Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]Dominique Elias
Département de Chirurgie Générale Carcinologique, Institut Gustave Roussy, rue Camille Desmoulins, 94805, Villejuif Cedex
Gastroenterol Clin Biol 27:407-12. 2003..The aim of this prospective study was to evaluate this treatment strategy...
